Aptose Biosciences Inc. (APTO)
1.71
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
0.00% (1D)
| Bid | 1.25 |
| Market Cap | 4.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.39M |
| EPS (ttm) | -36.38 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.09 |
| Analyst | Strong Buy |
| Ask | 2.17 |
| Volume | 648,213 |
| Avg. Volume (20D) | 231,156 |
| Open | 1.99 |
| Previous Close | 1.71 |
| Day's Range | 1.71 - 1.99 |
| 52-Week Range | 1.10 - 45.60 |
| Beta | 1.13 |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 1992
Employees 35
Stock Exchange NASDAQ
Ticker Symbol APTO
Website https://www.aptose.com
Analyst Forecast
According to 2 analyst ratings, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is $93, which is an increase of 5338.60% from the latest price.
Stock Forecasts2 weeks ago
-45.71%
Aptose Biosciences shares are trading lower after ...
Unlock content with
Pro Subscription
1 month ago
+26.67%
Aptose shares are trading higher after a Cohort Safety Review Committee unanimously approved escalating the TUS dose from 40 mg to 80 mg in the Phase 1/2 TUSCANY trial.
